Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

The “Big Three” PBMs are kicking their suit up to the 8th Circuit and, in the meantime, are once again asking a Missouri district judge to halt the FTC’s administrative case against them.

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

Aetna Inc. and OptumHealth Care Solutions Inc. signed a settlement worth $8.35 million that’s aimed at resolving a class ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

A healthcare company targeted by U.S. Rep. Pat Ryan as part of a service probe said that its facilities have undergone much in the way of improvement since it acquired them. In a ...

U.S. Rep. Pat Ryan has launched a community inquiry effort into care quality and accessibility matters at Optum-owned medical ...

PGA Tour Commissioner Jay Monahan met with the media for nearly an hour on Tuesday at the Players Championship Media Center.

The promise of integrated care is well understood: better patient outcomes, more efficient use of NHS resources and a more ...